These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37994573)

  • 21. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.
    Noone D; Al-Matrafi J; Tinckam K; Zipfel PF; Herzenberg AM; Thorner PS; Pluthero FG; Kahr WH; Filler G; Hebert D; Harvey E; Licht C
    Am J Transplant; 2012 Sep; 12(9):2546-53. PubMed ID: 22681773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of anticomplement therapy in the management of the kidney allograft.
    Kanbay M; Copur S; Yilmaz ZY; Baydar DE; Bilge I; Susal C; Kocak B; Ortiz A
    Clin Transplant; 2024 Mar; 38(3):e15277. PubMed ID: 38485664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept.
    Favi E; Cresseri D; Perego M; Ikehata M; Iesari S; Campise MR; Morello W; Testa S; Sioli V; Mattinzoli D; Longhi E; Del Gobbo A; Castellano G; Ferraresso M
    Clin Immunol; 2024 Jul; 264():110240. PubMed ID: 38734036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Yelken B; Arpalı E; Görcin S; Kocak B; Karatas C; Demiralp E; Turkmen A
    Transplant Proc; 2015; 47(6):1754-9. PubMed ID: 26293046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Eculizumab Use in Renal Transplant Recipients.
    Norville K; Stephen J; Mead-Harvey C; Corey R; Votruba C
    Prog Transplant; 2023 Jun; 33(2):162-167. PubMed ID: 36940100
    [No Abstract]   [Full Text] [Related]  

  • 28. Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation.
    West-Thielke P; Progar K; Campara M; Jasiak N; Gallon L; Tang I; Spaggiari M; Tzvetanov I; Benedetti E
    Transplant Proc; 2018; 50(1):66-69. PubMed ID: 29407333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports.
    González-Roncero F; Suñer M; Bernal G; Cabello V; Toro M; Pereira P; Angel Gentil M
    Transplant Proc; 2012 Nov; 44(9):2690-4. PubMed ID: 23146495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
    Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
    Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.
    González CC; López-Jiménez V; Vázquez-Sánchez T; Vázquez-Sánchez E; Cabello M; Hernández-Marrero D
    Transplant Proc; 2022; 54(1):25-26. PubMed ID: 34906374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
    Patriquin CJ; Kuo KHM
    Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.
    Kocak B; Arpali E; Demiralp E; Yelken B; Karatas C; Gorcin S; Gorgulu N; Uzunalan M; Turkmen A; Kalayoglu M
    Transplant Proc; 2013 Apr; 45(3):1022-5. PubMed ID: 23622614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.